Total Payments
$239,868
2024 Payments
$88,609
Companies
19
Transactions
204
Medicare Patients
289
Medicare Billing
$22,832
Payment Breakdown by Category
Consulting$147,244 (61.4%)
Research$53,144 (22.2%)
Travel$21,368 (8.9%)
Other$12,832 (5.3%)
Food & Beverage$4,405 (1.8%)
Education$874.20 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $147,244 | 67 | 61.4% |
| Unspecified | $53,144 | 3 | 22.2% |
| Travel and Lodging | $21,368 | 40 | 8.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,040 | 3 | 2.9% |
| Honoraria | $5,792 | 1 | 2.4% |
| Food and Beverage | $4,405 | 62 | 1.8% |
| Education | $874.20 | 28 | 0.4% |
Payments by Type
General
$186,723
201 transactions
Research
$53,144
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $50,816 | 1 | $0 (2024) |
| GE HEALTHCARE | $43,285 | 2 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $37,416 | 55 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $37,326 | 24 | $0 (2024) |
| Amgen Inc. | $22,448 | 39 | $0 (2024) |
| Novo Nordisk Inc | $18,000 | 6 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $7,668 | 43 | $0 (2020) |
| Aidoc Medical Ltd | $7,050 | 2 | $0 (2024) |
| Kastle Therapeutics LLC | $6,261 | 6 | $0 (2017) |
| Merck Sharp & Dohme LLC | $5,602 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,609 | 31 | Eli Lilly and Company ($50,816) |
| 2023 | $13,069 | 16 | NOVARTIS PHARMACEUTICALS CORPORATION ($6,531) |
| 2022 | $13,350 | 19 | Regeneron Pharmaceuticals, Inc. ($9,945) |
| 2021 | $11,790 | 6 | Novo Nordisk Inc ($6,760) |
| 2020 | $19,909 | 27 | Amgen Inc. ($10,193) |
| 2019 | $10,208 | 20 | Regeneron Pharmaceuticals, Inc. ($9,376) |
| 2018 | $3,644 | 10 | Novartis Pharmaceuticals Corporation ($1,764) |
| 2017 | $79,289 | 75 | GE HEALTHCARE ($43,285) |
All Payment Transactions
204 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/29/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $50,816.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 10/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/02/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/19/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $754.00 | General |
| Category: Cardiology | ||||||
| 08/14/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 08/14/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 07/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $329.50 | General |
| Category: Obesity | ||||||
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 06/07/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $585.00 | General |
| 05/31/2024 | Novo Nordisk Inc | Wegovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,260.50 | General |
| Category: Obesity | ||||||
| 05/09/2024 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $754.00 | General |
| Category: Cardiology | ||||||
| 05/08/2024 | Aidoc Medical Ltd | BriefCase (Device) | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| Category: medical device | ||||||
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 04/26/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 04/17/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 04/17/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 04/16/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 04/10/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,262.00 | General |
| 04/09/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $88.27 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $43.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $27.91 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $50,816 | 1 |
| CTQJ230A12001 | Novartis Pharmaceuticals Corporation | $1,807 | 1 |
| MENDEL2 Monotherapy | Amgen Inc. | $521.14 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 89 | 92 | $26,510 | $6,905 |
| 2022 | 5 | 77 | 78 | $19,830 | $5,804 |
| 2021 | 4 | 67 | 69 | $19,935 | $5,730 |
| 2020 | 4 | 56 | 58 | $14,169 | $4,393 |
Total Patients
289
Total Services
297
Medicare Billing
$22,832
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $9,338 | $2,420 | 25.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 35 | $8,380 | $2,103 | 25.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $6,732 | $1,778 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 13 | $2,060 | $604.57 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 26 | 27 | $5,893 | $1,857 | 31.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $4,914 | $1,418 | 28.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 13 | 13 | $4,862 | $1,350 | 27.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,266 | $645.10 | 28.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,895 | $533.92 | 28.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 27 | $10,098 | $2,781 | 27.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 19 | $4,085 | $1,295 | 31.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $4,212 | $1,206 | 28.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 11 | 11 | $1,540 | $448.42 | 29.1% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $4,845 | $1,547 | 31.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $4,187 | $1,415 | 33.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 15 | $3,043 | $884.37 | 29.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 14 | 15 | $2,094 | $546.60 | 26.1% |
About Dr. Michael Shapiro, DO
Dr. Michael Shapiro, DO is a Cardiovascular Disease healthcare provider based in Winston-Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1215063920.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Shapiro, DO has received a total of $239,868 in payments from pharmaceutical and medical device companies, with $88,609 received in 2024. These payments were reported across 204 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($147,244).
As a Medicare-enrolled provider, Shapiro has provided services to 289 Medicare beneficiaries, totaling 297 services with total Medicare billing of $22,832. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Winston-Salem, NC
- Active Since 02/26/2007
- Last Updated 06/28/2022
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1215063920
Products in Payments
- OMNISCAN (Drug) $43,285
- Repatha (Biological) $15,459
- LEQVIO (Drug) $14,019
- PRALUENT ALIROCUMAB INJECTION (Biological) $10,517
- PRALUENT (Biological) $9,376
- ILARIS (Biological) $8,830
- PELACARSEN (Drug) $7,200
- BriefCase (Device) $7,050
- Victoza (Drug) $6,750
- Wegovy (Drug) $6,590
- KYNAMRO (Drug) $6,261
- Kanuma (Drug) $5,708
- ISOVUE (Drug) $1,776
- ENTRESTO (Drug) $1,764
- ACZ885M (Biological) $1,211
- Livalo (Drug) $508.59
- PRALUENT (Drug) $218.29
- EVENITY (Biological) $195.66
- JANUVIA (Drug) $119.56
- NEXLIZET (Drug) $107.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.